Rabu, 07 April 2021

COVID-19: First dose of Moderna vaccine given in UK as 24-year-old carer Elle Taylor gets jab - Sky News

A 24-year-old carer has become the first person in the UK to receive the Moderna vaccine as it becomes the latest jab used in the country's vaccination programme.

Elle Taylor, from Ammanford in Wales, who is an unpaid carer for her 82-year-old grandmother, received the vaccine this morning.

"I'm very excited and very happy," she said. "I'm an unpaid carer for my grandmother so it is very important to me that I get it, so I can care for her properly and safely.

"My grandmother has had her first dose and she is going for her second dose on Saturday."

Live COVID updates from across the UK and around the world

Miss Taylor, who works at a further education college in Llanelli, received the Moderna jab from staff nurse Laura French at West Wales General Hospital in Carmathen.

She said she only found out on Tuesday evening that she was to be the first Briton to receive the Moderna jab in the UK.

More from Covid-19

First doses of the Moderna jab are being administered at West Wales General Hospital on Wednesday, with a total of 5,000 doses having been distributed to vaccination centres across Carmarthenshire, Ceredigion and Pembrokeshire.

Supplies of the Moderna vaccine arrived in Wales on Tuesday.

Moderna's vaccine is the third to be approved for use in the UK, and is being rolled out alongside jabs from Pfizer-BioNTech and Oxford University-AstraZeneca.

The UK has purchased 17 million doses of the Moderna jab, enough for 8.5 million people, and phase three results suggest the vaccine has 100% efficacy against severe cases of coronavirus.

Prime Minister Boris Johnson urged people to "please get your jab as soon as you are contacted".

Health Secretary Matt Hancock said: "I'm delighted we can start the UK rollout of the Moderna vaccine in west Wales today.

"The UK government has secured vaccines on behalf of the entire nation and the vaccination programme has shown our country working together at its best.

"Three out of every five people across the whole United Kingdom have received at least one dose, and today we start with the third approved vaccine. Wherever you live, when you get the call, get the jab."

Wales health minister Vaughan Gething added that the introduction of a third vaccine "significantly adds to our defences in the face of coronavirus and will help protect our most vulnerable".

UK government minister Paul Scully told Sky News the Moderna jab would be "coming to England and the other devolved nations across the next few days".

"You've heard the vaccines minister Nadhim Zahawi talk about the third week of April, we're already just about to start the second week of April so that's not too long to wait to get that third vaccine up and running," he added.

Scotland received its first batch of Moderna vaccines on Monday.

According to Moderna, no serious safety concerns have been identified among those who have taken its vaccine. Severe events after the first dose have included pain around the injection site, while some have reported fatigue, muscle pain, joint pain and headaches after receiving their second dose.

The UK now has three vaccines approved - from Pfizer, AstraZeneca and Moderna. Pic: AP
Image: The UK now has three vaccines approved - from Pfizer, AstraZeneca and Moderna. Pic: AP

It comes after a trial of the Oxford-AstraZeneca COVID-19 vaccine on children in the UK was paused while the medicines regulator investigates a possible link between the jab and rare blood clots in adults.

A University of Oxford spokesperson stressed that there were "no safety concerns" with this specific study, but that further information was being awaited from the Medicines and Healthcare products Regulatory Agency (MHRA).

Please use Chrome browser for a more accessible video player

Concerns raised over Oxford vaccine

A spokesperson for the Department of Health and Social Care said: "No decisions have been made on whether children should be offered vaccinations.

"We will be guided by the advice of our experts on these issues including the independent MHRA and Joint Committee on Vaccines and Immunisation."

Please use Chrome browser for a more accessible video player

'MHRA will only vaccinate when it's safe

Over the weekend, it was reported that there had been 30 blood clotting cases recorded by the MHRA out of more than 18 million doses of the AstraZeneca shot administered.

The MHRA confirmed that of those 30 people, seven had died as of 24 March.

The World Health Organisation maintains that the benefits of this vaccine outweigh any risks.

Adam Finn, professor of paediatrics at the University of Bristol, said: "There are some things that are very clear. The first is that these cases are very rare indeed. The second is that the vaccines that are available and in use in the UK prevent COVID very effectively."

He added: "In short, if you are currently being offered a dose of Oxford-AstraZeneca vaccine, your chances of remaining alive and well will go up if you take the vaccine and will go down if you don't."

Analysis: Could safety concerns derail UK's vaccine rollout?
By Ashish Joshi, health correspondent

The ongoing safety concerns about the AstraZeneca-Oxford vaccine do not seem to have crossed the Channel. At least not yet.

The possible link between it and a rare type of blood clot has been around for a few weeks now.

Some governments in Europe have decided that they will not administer the jab to younger people.

That is against the advice of European Medicines Agency and the World Health Organisation.

But could these safety concerns actually derail the UK's phenomenal vaccine rollout? Potentially yes, but realistically it is unlikely. There are a number of reasons.

Vaccine hesitancy in much more culturally entrenched on the continent, especially in France and Germany. It is not as serious here among the wider population.

But clearly there are parts of the population where it is a concern, like our black and ethnic minority communities.

Also the rollout has been so successful that we are working through our target groups very quickly.

These are the ones who are most at risk: the clinically vulnerable and the elderly.

We know that our senior citizens are most compliant where vaccines are concerned.

Hesitancy becomes more prevalent in younger people. By the time we get round to vaccinating the under-40s, more vaccines will be on stream.

So if there is still uncertainty over the Oxford vaccine then it is possible an alternative can be administered.

This was simply not possible at the start of the rollout - the urgency demanded speed and scale.

For now the most significant bump in the road is the dramatic slowdown in the number of people being vaccinated. The Easter bank holidays could be a factor, and so is vaccine supply.

We were warned that this would happen. The government's own scientists have forecast a significant drop in vaccine doses being administered until the end of July.

But that has not dented the government's confidence. It says we are still on track to meet its target of vaccinating all adults by the end of July.

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMigAFodHRwczovL25ld3Muc2t5LmNvbS9zdG9yeS9jb3ZpZC0xOS1maXJzdC1kb3NlLW9mLW1vZGVybmEtdmFjY2luZS1naXZlbi1pbi11ay1hcy0yNC15ZWFyLW9sZC1jYXJlci1lbGxlLXRheWxvci1nZXRzLWphYi0xMjI2ODA3NNIBhAFodHRwczovL25ld3Muc2t5LmNvbS9zdG9yeS9hbXAvY292aWQtMTktZmlyc3QtZG9zZS1vZi1tb2Rlcm5hLXZhY2NpbmUtZ2l2ZW4taW4tdWstYXMtMjQteWVhci1vbGQtY2FyZXItZWxsZS10YXlsb3ItZ2V0cy1qYWItMTIyNjgwNzQ?oc=5

2021-04-07 08:37:30Z
52781491296352

COVID-19: First dose of Moderna vaccine given in UK as 24-year-old carer Elle Taylor gets jab - Sky News

A 24-year-old carer has become the first person in the UK to receive the Moderna vaccine as it becomes the latest jab used in the country's vaccination programme.

Elle Taylor, from Ammanford in Wales, who is an unpaid carer for her 82-year-old grandmother, received the vaccine this morning.

First doses of the jab are being administered at West Wales General Hospital in Carmarthen - and a total of 5,000 doses have been distributed to vaccination centres.

Moderna's vaccine is the third to be approved for use in the UK, and is being rolled out alongside jabs from Pfizer-BioNTech and Oxford University-AstraZeneca.

Live COVID updates from across the UK and around the world

The UK has purchased 17 million doses of the Moderna jab, enough for 8.5 million people, and phase three results suggest the vaccine has 100% efficacy against severe cases of coronavirus.

Prime Minister Boris Johnson urged people to "please get your jab as soon as you are contacted".

More from Covid-19

Health Secretary Matt Hancock said: "I'm delighted we can start the UK rollout of the Moderna vaccine in west Wales today.

"The UK government has secured vaccines on behalf of the entire nation and the vaccination programme has shown our country working together at its best.

"Three out of every five people across the whole United Kingdom have received at least one dose, and today we start with the third approved vaccine. Wherever you live, when you get the call, get the jab."

Wales health minister Vaughan Gething added that the introduction of a third vaccine "significantly adds to our defences in the face of coronavirus and will help protect our most vulnerable".

UK government minister Paul Scully told Sky News the Moderna jab would be "coming to England and the other devolved nations across the next few days".

"You've heard the vaccines minister Nadhim Zahawi talk about the third week of April, we're already just about to start the second week of April so that's not too long to wait to get that third vaccine up and running," he added.

Scotland received its first batch of Moderna vaccines on Monday.

According to Moderna, no serious safety concerns have been identified among those who have taken its vaccine. Severe events after the first dose have included pain around the injection site, while some have reported fatigue, muscle pain, joint pain and headaches after receiving their second dose.

The UK now has three vaccines approved - from Pfizer, AstraZeneca and Moderna. Pic: AP
Image: The UK now has three vaccines approved - from Pfizer, AstraZeneca and Moderna. Pic: AP

It comes after a trial of the Oxford-AstraZeneca COVID-19 vaccine on children in the UK was paused while the medicines regulator investigates a possible link between the jab and rare blood clots in adults.

A University of Oxford spokesperson stressed that there were "no safety concerns" with this specific study, but that further information was being awaited from the Medicines and Healthcare products Regulatory Agency (MHRA).

Please use Chrome browser for a more accessible video player

Concerns raised over Oxford vaccine

A spokesperson for the Department of Health and Social Care said: "No decisions have been made on whether children should be offered vaccinations.

"We will be guided by the advice of our experts on these issues including the independent MHRA and Joint Committee on Vaccines and Immunisation."

Please use Chrome browser for a more accessible video player

'MHRA will only vaccinate when it's safe

Over the weekend, it was reported that there had been 30 blood clotting cases recorded by the MHRA out of more than 18 million doses of the AstraZeneca shot administered.

The MHRA confirmed that of those 30 people, seven had died as of 24 March.

The World Health Organisation maintains that the benefits of this vaccine outweigh any risks.

Adam Finn, professor of paediatrics at the University of Bristol, said: "There are some things that are very clear. The first is that these cases are very rare indeed. The second is that the vaccines that are available and in use in the UK prevent COVID very effectively."

He added: "In short, if you are currently being offered a dose of Oxford-AstraZeneca vaccine, your chances of remaining alive and well will go up if you take the vaccine and will go down if you don't."

Analysis: Could safety concerns derail UK's vaccine rollout?
By Ashish Joshi, health correspondent

The ongoing safety concerns about the AstraZeneca-Oxford vaccine do not seem to have crossed the Channel. At least not yet.

The possible link between it and a rare type of blood clot has been around for a few weeks now.

Some governments in Europe have decided that they will not administer the jab to younger people.

That is against the advice of European Medicines Agency and the World Health Organisation.

But could these safety concerns actually derail the UK's phenomenal vaccine rollout? Potentially yes, but realistically it is unlikely. There are a number of reasons.

Vaccine hesitancy in much more culturally entrenched on the continent, especially in France and Germany. It is not as serious here among the wider population.

But clearly there are parts of the population where it is a concern, like our black and ethnic minority communities.

Also the rollout has been so successful that we are working through our target groups very quickly.

These are the ones who are most at risk: the clinically vulnerable and the elderly.

We know that our senior citizens are most compliant where vaccines are concerned.

Hesitancy becomes more prevalent in younger people. By the time we get round to vaccinating the under-40s, more vaccines will be on stream.

So if there is still uncertainty over the Oxford vaccine then it is possible an alternative can be administered.

This was simply not possible at the start of the rollout - the urgency demanded speed and scale.

For now the most significant bump in the road is the dramatic slowdown in the number of people being vaccinated. The Easter bank holidays could be a factor, and so is vaccine supply.

We were warned that this would happen. The government's own scientists have forecast a significant drop in vaccine doses being administered until the end of July.

But that has not dented the government's confidence. It says we are still on track to meet its target of vaccinating all adults by the end of July.

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMigAFodHRwczovL25ld3Muc2t5LmNvbS9zdG9yeS9jb3ZpZC0xOS1maXJzdC1kb3NlLW9mLW1vZGVybmEtdmFjY2luZS1naXZlbi1pbi11ay1hcy0yNC15ZWFyLW9sZC1jYXJlci1lbGxlLXRheWxvci1nZXRzLWphYi0xMjI2ODA3NNIBhAFodHRwczovL25ld3Muc2t5LmNvbS9zdG9yeS9hbXAvY292aWQtMTktZmlyc3QtZG9zZS1vZi1tb2Rlcm5hLXZhY2NpbmUtZ2l2ZW4taW4tdWstYXMtMjQteWVhci1vbGQtY2FyZXItZWxsZS10YXlsb3ItZ2V0cy1qYWItMTIyNjgwNzQ?oc=5

2021-04-07 08:22:31Z
52781491296352

Covid-19: Moderna vaccine rollout to begin and Brazil daily deaths top 4,000 - BBC News

Here are five things you need to know about the coronavirus pandemic this Wednesday morning. We'll have another update for you this evening.

1. Moderna Covid vaccine rollout to begin

A third Covid-19 vaccine will be rolled out in the UK later. The Moderna vaccine follows the Pfizer-BioNTech and Oxford-AstraZeneca jabs, which are already widely in use. Seventeen million doses were ordered by the government and Wales will become the first nation to administer the two-dose vaccine in Carmarthenshire later today. Wales Health Minister Vaughan Gething says a third vaccine "significantly adds" to defences against Covid-19. "Every vaccine given to someone in Wales is a small victory against the virus," he says. Scotland has received its first Moderna batch but not confirmed a rollout date. Neither has England, but yesterday the UK government's vaccines minister Nadhim Zahawi said the Moderna vaccine would be deployed "around the third week of April".

Three Covid-19 vaccines
Getty Images
Short presentational grey line

2. Brazil daily Covid deaths top 4,000 for first time

Brazil has recorded more than 4,000 Covid-related deaths in 24 hours for the first time, as a more contagious variant fuels a surge in cases. Hospitals are overcrowded, with people dying as they wait for treatment in some cities, and the health system is on the brink of collapse in many areas. The country's total death toll is now almost 337,000, second only to the US. But President Jair Bolsonaro continues to oppose any lockdown measures to curb the outbreak. He argues that the damage to the economy would be worse than the effects of the virus itself, and has tried to revert some of the restrictions imposed by local authorities in the courts.

Woman reacts during the burial of her mother in Manaus
Reuters
Short presentational grey line

3. Covid-19 raises risk of depression and dementia, study suggests

Covid-19 raises the risk of depression, dementia, psychosis and stroke, a study finds. A third of those with a previous Covid infection went on to develop or have a relapse of a psychological or neurological condition but those admitted to hospital or in intensive care had an even higher risk. This is likely to be down to both the effects of stress, and the virus having a direct impact on the brain. UK scientists looked at the electronic medical records from the previous six months of more than half a million patients in the US, and their chances of developing one of 14 common psychological or neurological conditions.

medics wheeling bed through corridor
Getty Images
Short presentational grey line

4. Schools 'a lifeline to many students' in past year'

School staff have been giving clothing, food and furnishings to families that have been struggling financially in the coronavirus pandemic, teachers say. Some pupils have gone to school without winter coats, while others have been worried about having enough to eat, a National Education Union poll suggests. The Department for Education says it has invested £2bn to help pupils in England in the wake of the pandemic.

Arriving at school
Jane Barlow
Short presentational grey line

5. US faces ketchup shortage amid pandemic

The US is facing shortages of tomato ketchup after the coronavirus pandemic led to a surge in demand for sachets of the popular condiment. Heinz, the most widely sold brand of ketchup, says the rise in demand had been "driven by... accelerated delivery and take-out trends". The packs often accompany delivery orders and have effectively replaced the bottles kept on restaurant tables. The company says it has stepped up production.

Close-up of container of Heinz brand ketchup packets in restaurant setting, Lafayette, California, November 6, 2020.
Getty Images
line

And don't forget...

Find more information, advice and guides on our coronavirus page. What's happening with pools, gyms and hairdressers when lockdown restrictions ease in England on 12 April? Find out everything you need to know here.

Government statistics show 126,882 people have now died, up 20 in the latest 24-hour period. In total 4,364,529 people have tested positive, up 2,379. while there are 3,536 people in hospital. In total 31,622,367 people have received their first vaccination, up 40,744 in the latest 24-hour period. Updated 6 April.
line
YQA logo

What questions do you have about coronavirus?

In some cases, your question will be published, displaying your name, age and location as you provide it, unless you state otherwise. Your contact details will never be published. Please ensure you have read our terms & conditions and privacy policy.

Use this form to ask your question:

If you are reading this page and can't see the form you will need to visit the mobile version of the BBC website to submit your question or send them via email to YourQuestions@bbc.co.uk. Please include your name, age and location with any question you send in.

Around the BBC - Sounds
Around the BBC footer - Sounds

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiJmh0dHBzOi8vd3d3LmJiYy5jby51ay9uZXdzL3VrLTU2NjU1ODY40gEqaHR0cHM6Ly93d3cuYmJjLmNvLnVrL25ld3MvYW1wL3VrLTU2NjU1ODY4?oc=5

2021-04-07 06:54:28Z
52781491296352

COVID-19: 'Another key milestone' as Moderna vaccine rollout begins in the UK - Sky News

The Moderna vaccine is going to be given to patients in the UK for the first time today.

First doses of the jab are going to be administered at West Wales General Hospital in Carmarthen - and a total of 5,000 doses have been distributed to vaccination centres.

Moderna's vaccine is the third to be approved for use in the UK, and will be rolled out alongside jabs from Pfizer-BioNTech and Oxford University-AstraZeneca.

Live COVID updates from across the UK and around the world

The UK has purchased 17 million doses of the Moderna jab, enough for 8.5 million people, and phase three results suggest the vaccine has 100% efficacy against severe cases of coronavirus.

Prime Minister Boris Johnson urged people to "please get your jab as soon as you are contacted".

Health Secretary Matt Hancock said: "I'm delighted we can start the UK rollout of the Moderna vaccine in west Wales today.

More from Covid-19

"The UK government has secured vaccines on behalf of the entire nation and the vaccination programme has shown our country working together at its best.

"Three out of every five people across the whole United Kingdom have received at least one dose, and today we start with the third approved vaccine. Wherever you live, when you get the call, get the jab."

Wales health minister Vaughan Gething added that the introduction of a third vaccine "significantly adds to our defences in the face of coronavirus and will help protect our most vulnerable".

The UK now has three vaccines approved - from Pfizer, AstraZeneca and Moderna. Pic: AP
Image: The UK now has three vaccines approved - from Pfizer, AstraZeneca and Moderna. Pic: AP

UK government minister Paul Scully told Sky News the Moderna jab would be "coming to England and the other devolved nations across the next few days".

"You've heard the vaccines minister Nadhim Zahawi talk about the third week of April, we're already just about to start the second week of April so that's not too long to wait to get that third vaccine up and running," he added.

Scotland received its first batch of Moderna vaccines on Monday.

According to Moderna, no serious safety concerns have been identified among those who have taken its vaccine. Severe events after the first dose have included pain around the injection site, while some have reported fatigue, muscle pain, joint pain and headaches after receiving their second dose.

Please use Chrome browser for a more accessible video player

Concerns raised over Oxford vaccine

It comes after a trial of the Oxford-AstraZeneca COVID-19 vaccine on children in the UK was paused while the medicines regulator investigates a possible link between the jab and rare blood clots in adults.

A University of Oxford spokesperson stressed that there were "no safety concerns" with this specific study, but that further information was being awaited from the Medicines and Healthcare products Regulatory Agency (MHRA).

Please use Chrome browser for a more accessible video player

'MHRA will only vaccinate when it's safe

A spokesperson for the Department of Health and Social Care said: "No decisions have been made on whether children should be offered vaccinations.

"We will be guided by the advice of our experts on these issues including the independent MHRA and Joint Committee on Vaccines and Immunisation."

Over the weekend, it was reported that there had been 30 blood clotting cases recorded by the MHRA out of more than 18 million doses of the AstraZeneca shot administered.

The MHRA confirmed that of those 30 people, seven had died as of 24 March.

The World Health Organisation maintains that the benefits of this vaccine outweigh any risks.

Adam Finn, professor of paediatrics at the University of Bristol, said: "There are some things that are very clear. The first is that these cases are very rare indeed. The second is that the vaccines that are available and in use in the UK prevent COVID very effectively."

He added: "In short, if you are currently being offered a dose of Oxford-AstraZeneca vaccine, your chances of remaining alive and well will go up if you take the vaccine and will go down if you don't."

Analysis: Could safety concerns derail UK's vaccine rollout?
By Ashish Joshi, health correspondent

The ongoing safety concerns about the AstraZeneca-Oxford vaccine do not seem to have crossed the Channel. At least not yet.

The possible link between it and a rare type of blood clot has been around for a few weeks now.

Some governments in Europe have decided that they will not administer the jab to younger people.

That is against the advice of European Medicines Agency and the World Health Organisation.

But could these safety concerns actually derail the UK's phenomenal vaccine rollout? Potentially yes, but realistically it is unlikely. There are a number of reasons.

Vaccine hesitancy in much more culturally entrenched on the continent, especially in France and Germany. It is not as serious here among the wider population.

But clearly there are parts of the population where it is a concern, like our black and ethnic minority communities.

Also the rollout has been so successful that we are working through our target groups very quickly.

These are the ones who are most at risk: the clinically vulnerable and the elderly.

We know that our senior citizens are most compliant where vaccines are concerned.

Hesitancy becomes more prevalent in younger people. By the time we get round to vaccinating the under-40s, more vaccines will be on stream.

So if there is still uncertainty over the Oxford vaccine then it is possible an alternative can be administered.

This was simply not possible at the start of the rollout - the urgency demanded speed and scale.

For now the most significant bump in the road is the dramatic slowdown in the number of people being vaccinated. The Easter bank holidays could be a factor, and so is vaccine supply.

We were warned that this would happen. The government's own scientists have forecast a significant drop in vaccine doses being administered until the end of July.

But that has not dented the government's confidence. It says we are still on track to meet its target of vaccinating all adults by the end of July.

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMicmh0dHBzOi8vbmV3cy5za3kuY29tL3N0b3J5L25ldy10eXBlLW9mLXZhY2NpbmUtdG8tYmUtZ2l2ZW4tdG8tcGF0aWVudHMtaW4tdGhlLXVrLWZvci10aGUtZmlyc3QtdGltZS10b2RheS0xMjI2ODA3NNIBdmh0dHBzOi8vbmV3cy5za3kuY29tL3N0b3J5L2FtcC9uZXctdHlwZS1vZi12YWNjaW5lLXRvLWJlLWdpdmVuLXRvLXBhdGllbnRzLWluLXRoZS11ay1mb3ItdGhlLWZpcnN0LXRpbWUtdG9kYXktMTIyNjgwNzQ?oc=5

2021-04-07 03:00:00Z
52781491296352

Selasa, 06 April 2021

Holyrood 2021: Beware the bogeyman - BBC News

Boris Johnson, Nicola Sturgeon and Alex Salmond
Getty Images

The Holyrood election campaign is in full flow ahead of voters going to the polls on 6 May. Nicola Sturgeon is hoping to continue as first minister, but what battles is she facing?

2px presentational grey line

There are two bogeymen in Nicola Sturgeon's election campaign. One she chooses. The other she desperately wishes to be without.

Boris Johnson is her bogeyman of choice. His name has featured in at least 20 SNP news releases I have received in the last week.

Why? Because Mr Johnson is not very popular in Scotland and if the choice in this election was between his leadership and that of Ms Sturgeon, she would expect to win a landslide.

Of course, he is not a Holyrood candidate. But the SNP leader still finds him useful in making her case for another independence referendum when Covid eases.

She argues that Scotland should have the "right to choose between independence or Westminster governments led by the likes of Boris Johnson".

The framing of this choice infuriates many pro-UK politicians because Mr Johnson is, like any prime minister, only temporary whereas independence is for keeps.

They also think the success of the UK vaccination programme and Treasury support schemes like furlough help to make the case for Scotland's continued participation in the union.

Anyway, the SNP has co-opted Mr Johnson into their campaign just as the Conservatives have used Ms Sturgeon as their bogeywoman in the past.

'Negative messaging'

Think of those Tory billboards in 2015 featuring Nicola Sturgeon with the then Labour leader Ed Miliband in her pocket and the Daily Mail wondering if she was "the most dangerous woman in Britain".

It is commonplace for political campaigns to use a combination of this kind of negative messaging alongside what they consider the positive attributes of their own party's policies and personalities.

That much is within their control. Much else is not. And that's where Nicola Sturgeon's unwanted bogeyman comes in.

His name is Alex Salmond, the leader of the new pro-independence party, Alba.

Not only is his presence in this campaign a constant reminder of their toxic feud over harassment complaints, he is also competing directly with the SNP for votes on the regional lists.

Mr Salmond argues that if people back Alba in sufficient numbers it will harm pro-UK parties and help create a supermajority for independence in the next parliament.

The SNP fear it could split the nationalist vote, potentially costing them seats and the opportunity to secure an overall majority on their own.

Ms Sturgeon has criticised her former mentor, ally and friend as a "gambler" and questioned his suitability for office, insisting she has "no intention" of working with him after the election.

Leaders at the debate

Initial polling (two samples) suggests that within a week of its formation Alba had the potential to attract between 3 and 6 percent support on the regional lists.

At the upper end of that scale they would be expected to start winning seats under Holyrood's more proportional voting system. If they fall much short of that they could get nothing.

'Awkward questions'

Having founded the gradualist step-by-step approach to independence as SNP leader, Mr Salmond now seems to have placed himself at the head of a new fundamentalism within the nationalist movement.

At a news conference on the 701st anniversary of the Declaration of Arbroath, Mr Salmond offered his own variation — that Scottish independence negotiations with the UK should begin within a week of the election if a large majority of MSPs support leaving the UK.

They do not necessarily think another referendum - which remains central to SNP thinking - would be required. Further differences over Scotland's currency options and approach to EU relations in the event of independence may follow.

Alba also seems to share the concern that gender self-identification could undermine women's rights, which sets them at odds with both the SNP leadership and the other independence supporting party at Holyrood, the Scottish Greens.

As their policy alternatives emerge, awkward questions for Nicola Sturgeon are likely to follow. She is more comfortable talking about another referendum in principle, rather than the nuts and bolts of independence.

While there are potential dangers in Mr Salmond's attempt at a political comeback for all parties, there is an upside for the Scottish Conservatives.

With Alba in the campaign, independence - the Tories' bogeyman of choice - is sure to remain prominent in the debate. That's something the Tories are keen on, to help motivate their unionist base.

Willie Rennie, Douglas Ross and Anas Sarwar
PA / Getty

The Scottish Tory leader, Douglas Ross, has perhaps less to gain from making Boris Johnson a big part of his campaign, although he has confirmed the prime minister will play a part.

Recent opinion polling suggests the only political leader less popular in Scotland than Mr Johnson is Mr Salmond. His negative ratings may limit his new party's potential to make inroads.

Douglas Ross declared himself sufficiently concerned about the emergence of Alba to re-issue an invitation to Labour and the Liberal Democrats to join him in a unionist alliance.

Both parties rejected his offer with Labour's Anas Sarwar accusing him of "petty game playing" and the Liberal Democrats' Willie Rennie describing Tory politics as "too dark and divisive".

The Lib Dems have not recovered from their five years in coalition with the Conservatives at Westminster and Scottish Labour bears the scars of its participation with the Tories in the Better version and Together campaign in 2014.

In this election, Mr Sarwar wants to beat the Tories into third place rather than campaign alongside them. The conflict between him and Mr Ross generated some of the sharpest exchanges in the BBC leaders' debate.

Independence may be the Conservative's bogeyman of choice but a revived Scottish Labour Party under Anas Sarwar could be the cause of some sleepless nights for Tory strategists.

They'll also want to keep an eye on George Galloway's Alliance for Unity party and what was the Brexit party - now Reform UK - competing for unionist votes on the regional lists.

In election 2021, beware the bogeymen.

banner
banner

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMiQWh0dHBzOi8vd3d3LmJiYy5jby51ay9uZXdzL3VrLXNjb3RsYW5kLXNjb3RsYW5kLXBvbGl0aWNzLTU2NjQ4NjE20gFFaHR0cHM6Ly93d3cuYmJjLmNvLnVrL25ld3MvYW1wL3VrLXNjb3RsYW5kLXNjb3RsYW5kLXBvbGl0aWNzLTU2NjQ4NjE2?oc=5

2021-04-06 21:55:18Z
52781494027049

COVID-19: UK trial of Oxford vaccine on children paused as regulator probes rare blood clots in adults - Sky News

A trial of the Oxford-AstraZeneca COVID vaccine on children in the UK has been paused while the medicines regulator investigates a possible link between the jab and rare blood clots in adults.

A University of Oxford spokesperson stressed that there were "no safety concerns" with this specific study, but that further information was being awaited from the Medicines and Healthcare products Regulatory Agency (MHRA).

"Whilst there are no safety concerns in the paediatric clinical trial, we await additional information from the MHRA on its review of rare cases of thrombosis/thrombocytopaenia that have been reported in adults, before giving any further vaccinations in the trial," the statement said.

"Parents and children should continue to attend all scheduled visits and can contact the trial sites if they have any questions."

The government has announced the scheme will replace the EU's Erasmum
Image: An Oxford University spokesperson has said they are awaiting information from the MHRA

A spokesperson for the Department of Health and Social Care said: "No decisions have been made on whether children should be offered vaccinations.

"We will be guided by the advice of our experts on these issues including the independent MHRA and Joint Committee on Vaccines and Immunisation."

Over the weekend it was reported that there had been 30 blood clotting cases recorded by the MHRA out of more than 18 million doses of the AstraZeneca shot administered.

More from Covid-19

The MHRA confirmed that of those 30 people, seven had died as of 24 March.

The European Medicines Agency's (EMA) head of vaccine strategy has said it is "increasingly difficult" to say there is "no cause and effect relationship" between the Oxford-AstraZeneca jab and "rare cases of unusual blood clots".

A press conference is expected from the European drug regulator either on Wednesday or Thursday, where its latest findings will be announced on the matter.

The World Health Organisation is also expected to report findings from an assessment this week, but has thus far maintained that the benefits of the vaccine outweigh any risks.

Responding to the decision to pause the trial involving children in the UK, SAGE adviser Professor Calum Semple told Channel 4: "This has been done out of exceptional caution and the big story still is that for a middle-aged, slightly overweight man, such as myself, my risk of death is one in 13,000 - the risk of this rare clot, which might not even be associated with the vaccine, is probably one in a million.

"So I'm still going to say it's better to get the vaccine than not get the vaccine and we can pause and take time to carefully consider the value for children because they're not at risk of death from COVID."

Adam Finn, professor of paediatrics at the University of Bristol, said: "There's a lot that remains unclear about the cases of thrombosis and thrombocytopenia being intensively studied by regulators and widely reported in the media.

"We need to know more about the people affected and we need to understand exactly how the illnesses came about, while many other questions remain unanswered at this time.

"However, there are some things that are very clear. The first is that these cases are very rare indeed. The second is that the vaccines that are available and in use in the UK prevent COVID very effectively."

He added: "In short, if you are currently being offered a dose of Oxford-AstraZeneca vaccine, your chances of remaining alive and well will go up if you take the vaccine and will go down if you don't."

The Oxford jab has been key to the UK's successful vaccine rollout thus far, with more than 31.6 people having been vaccinated and almost 5.5 million having had a second dose.

But the speed of the vaccination drive will slow over the coming weeks due to supply problems. However, the government still expects to meet its target of offering a jab to every adult by the end of July.

Let's block ads! (Why?)


https://news.google.com/__i/rss/rd/articles/CBMifWh0dHBzOi8vbmV3cy5za3kuY29tL3N0b3J5L3VrLXRyaWFsLW9mLW94Zm9yZC1jb3ZpZC1qYWItb24tY2hpbGRyZW4tcGF1c2VkLWFzLXJlZ3VsYXRvci1wcm9iZXMtYmxvb2QtY2xvdHMtaW4tYWR1bHRzLTEyMjY3Nzgw0gGBAWh0dHBzOi8vbmV3cy5za3kuY29tL3N0b3J5L2FtcC91ay10cmlhbC1vZi1veGZvcmQtY292aWQtamFiLW9uLWNoaWxkcmVuLXBhdXNlZC1hcy1yZWd1bGF0b3ItcHJvYmVzLWJsb29kLWNsb3RzLWluLWFkdWx0cy0xMjI2Nzc4MA?oc=5

2021-04-06 19:16:38Z
52781491296352